Royce & Associates LP Purchases 64,049 Shares of Cellebrite DI Ltd. $CLBT

Royce & Associates LP raised its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 214.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 93,942 shares of the company’s stock after purchasing an additional 64,049 shares during the period. Royce & Associates LP’s holdings in Cellebrite DI were worth $1,741,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Voss Capital LP increased its stake in shares of Cellebrite DI by 34.0% in the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock valued at $82,400,000 after purchasing an additional 1,306,398 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in Cellebrite DI by 17.1% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock valued at $62,608,000 after buying an additional 570,000 shares in the last quarter. Invesco Ltd. grew its position in Cellebrite DI by 6.4% in the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after acquiring an additional 209,473 shares during the last quarter. Pertento Partners LLP grew its position in Cellebrite DI by 11.8% in the second quarter. Pertento Partners LLP now owns 2,945,641 shares of the company’s stock valued at $47,130,000 after acquiring an additional 309,988 shares during the last quarter. Finally, Handelsbanken Fonder AB raised its stake in Cellebrite DI by 18.4% during the third quarter. Handelsbanken Fonder AB now owns 2,900,000 shares of the company’s stock worth $53,737,000 after acquiring an additional 450,000 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Bank of America lifted their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 13th. JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Lake Street Capital boosted their price objective on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $15.19 on Friday. Cellebrite DI Ltd. has a 52 week low of $11.76 and a 52 week high of $20.86. The firm has a market cap of $3.79 billion, a PE ratio of 49.00, a price-to-earnings-growth ratio of 2.17 and a beta of 1.30. The firm’s fifty day moving average is $15.67 and its 200-day moving average is $16.95.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.14. The business had revenue of $128.82 million during the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.Cellebrite DI’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period last year, the company earned $0.10 EPS. Sell-side analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.